Allowing Greater Access to Safe and Effective Contraception Act
Summary
HR8083 is an early-stage bill (referred to four committees) that would incentivize OTC switches for routine oral contraceptives via priority review and fee waivers for drugmakers. No explicit funding is authorized — only a GAO study on federal contraceptive funding is directed. At this procedural stage, the bill has zero binding market impact. Pfizer ($PFE at $26.69, down -4.95% over 30 days) and Bristol-Myers Squibb ($BMY at $59.64, down -1.67% over 30 days) have no current revenue exposure to this pathway.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8083 is early-stage with zero binding market impact — referred to four committees with no hearings scheduled.
- 2.No federal funding is authorized or appropriated; the bill only waives FDA user fees for OTC switch applications.
- 3.Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) have minimal contraceptive revenue exposure; the bill does not affect their primary businesses.
- 4.Pure-play contraceptive manufacturers (Teva, AbbVie) could see optionality benefits IF the bill passes AND they choose to file an OTC switch — both are uncertain.
- 5.No signal in price action: $PFE (-4.95% 30d) and $BMY (-1.67% 30d) show no correlation with this legislative action.
Market Implications
No immediate market implications. HR8083 is a procedural early-stage bill that creates no funding, no procurement, no tax changes, and no binding regulatory requirement. The OTC switch pathway is optional for manufacturers, and the bill's passage probability is low given its divided referral and lack of Senate companion. Retail investors should ignore this bill until (and unless) it advances to a committee markup, which would indicate real legislative momentum. Current price trends for ($26.69, trending down) and ($59.64, bouncing but trending down over 30 days) are driven by fundamentals (patent cliffs, pipeline sentiment, interest rates), not this bill.
Full Analysis
-
What happened: On March 25, 2026, Rep. Hinson (R-IA) introduced HR8083, the "Allowing Greater Access to Safe and Effective Contraception Act." The bill was referred to four committees — Energy and Commerce, Ways and Means, Natural Resources, and Armed Services — indicating a broad jurisdictional scope. This is the only action; the bill is in early-stage committee review with no markups or hearings scheduled. The bill's core mechanism is simple: it directs the FDA to grant priority review and waive application fees for any manufacturer filing a supplemental new drug application (sNDA) to switch an existing prescription oral contraceptive (for routine use, not emergency or abortifacient) to OTC status for adults age 18+. Individuals under 18 would remain prescription-only.
-
The money trail: There is NO direct federal spending or tax expenditure created by this bill. Section 2(c) waives the fee for the OTC switch application — that fee is typically ~$2M for a standard application requiring clinical data. The waiver reduces a private cost to drugmakers, not a federal outlay. Section 3 directs the GAO to conduct a study on federal funding of contraceptive methods — this is a study, not an appropriation. No funding is authorized or appropriated. The fiscal impact is limited to administrative costs for FDA review, which are already covered by user fees. This is an authorization bill with no appropriation rider.
-
Structural winners and losers: The primary beneficiaries would be drugmakers with existing oral contraceptive franchises who could afford the clinical trials required for an OTC switch. Teva ($TEVA, generic contraceptive leader), AbbVie ($ABBV through its legacy Allergan portfolio — Lo Loestrin FE, etc.), and Bayer (privately held, not tradeable on US exchanges) are the largest players in oral contraceptives. Among US-listed pure-plays, has legacy oral contraceptive products via its established products division (Nordette, Lo/Ovral generics) but this is a minimal revenue line. has no significant contraceptive portfolio post-Celgene integration. Neither company is structurally positioned to benefit significantly. The bill provides no direct procurement, no tax credits, and no guaranteed revenue. The impact is purely optional: it lowers the regulatory cost for manufacturers who choose to pursue OTC status. Given the early legislative stage (referred to four committees, no Senate companion), passage probability is low.
-
Market data context: As of April 30, 2026, trades at $26.69, near the bottom of its 52-week range ($21.97-$28.75), with a 30-day decline of -4.95% and a 7-day decline of -1.15%. trades at $59.64, near its 52-week high ($42.52-$62.89), showing a 7-day bounce of +1.58% but a 30-day decline of -1.67%. Neither stock shows any price action correlation to HR8083 — the bill's introduction date (March 25) shows no anomalous volume or price movement in either name. The current price trends reflect broader sector dynamics (sector rotation out of pharma, patent cliffs) rather than legislative catalysts.
-
Timeline: HR8083 has passed its only procedural hurdle — introduction and committee referral. It must now be considered by all four referred committees. Given the divided referral to Armed Services and Natural Resources (unusual for a contraceptive bill), jurisdictional disputes may slow progress. No companion bill exists in the Senate. For the bill to become law, it must pass both chambers in identical form and be signed by the President. No hearings have been scheduled. This is a low-velocity, early-stage procedural action with no market-moving potential in the near term.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Limited confirming evidence — causal thesis exists but few external signals
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Skinny Labels, Big Savings Act
Protect Infant Formula from Contamination Act
Most Favored Patient Act of 2026
Protecting Americans from Unsafe Drugs Act of 2026
Elijah E. Cummings Family Asthma Act
Biosimilar Red Tape Elimination Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Actions by the United States in the Investigations under Section 301 of the Trade Act of 1974 of the Acts, Policies, and Practices of 60 Economies Related to the Failure of Each Economy to Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced with Forced Labor
This Presidential Memorandum directs the U.S. Trade Representative to impose Section 301 tariffs on imports from 60 economies due to their failure to prohibit or effectively enforce forced labor import bans. Tariffs are set at 10% ad valorem for certain economies with partial enforcement or commitments, and 12.5% for others, with exemptions for raw materials and products causing domestic supply issues, and plans for textile tariff-rate quotas by September 2026. The action aims to eliminate the identified unreasonable trade practices through these tariffs and incentives.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →